Literature DB >> 4595080

Properties of strains of Escherichia coli carried in different phases of ulcerative colitis.

E M Cooke, S P Ewins, J Hywel-Jones, J E Lennard-Jones.   

Abstract

Strains of E. coli from the faeces of patients with active ulcerative colitis and with colitis in remission were examined for haemolysin and necrotoxin production. Cultures from 63 patients with active colitis grew haemolytic E. coli in 23 (37%) as compared with 24 (21%) from 115 patients whose disease was in remission (p < 0.05). The corresponding proportions for necrotoxin-producing strains were 22% and 12%. Of 35 patients investigated both in relapse and remission of the colitis, 14 changed their carriage of haemolytic E. coli. Thirteen of these carried haemolytic organisms in relapse but not in remission, and one carried haemolytic organisms in remission but not in relapse (p < 0.01). Strains of E. coli were also examined from specimens of faeces obtained at weekly intervals for 28 weeks from 19 patients. The acquisition of haemolytic or necrotoxic E. coli strains tended to follow rather than precede the onset of the attack in the four patients who developed a relapse of the disease during this period. Among these 19 patients haemolytic and necrotoxic strains were found most commonly when blood was regularly present in the faeces. These facts suggest that conditions in the bowel during a relapse of colitis tend to favour the presence of haemolysin- and necrotoxin-producing organisms, rather than that these organisms cause the relapse. Of 50 strains of E. coli from patients treated with sulphasalazine tested for sensitivity to sulphapyridine 49 were resistant. There was no clear relation between the activity of the colitis and the presence of any of the 27 serotypes of E. coli examined.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4595080      PMCID: PMC1412904          DOI: 10.1136/gut.15.2.143

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  7 in total

1.  PREDNISONE AS MAINTENANCE TREATMENT FOR ULCERATIVE COLITIS IN REMISSION.

Authors:  J E LENNARD-JONES; J J MISIEWICZ; A M CONNELL; J H BARON; F A JONES
Journal:  Lancet       Date:  1965-01-23       Impact factor: 79.321

2.  Persistence of individual strains of Escherichia coli in the intestinal tract of man.

Authors:  H J SEARS; I BROWNLEE; J K UCHIYAMA
Journal:  J Bacteriol       Date:  1950-02       Impact factor: 3.490

3.  Fate of ingested Escherichia coli in normal persons.

Authors:  E M Cooke; I G Hettiaratchy; A C Buck
Journal:  J Med Microbiol       Date:  1972-08       Impact factor: 2.472

4.  Studies of intestinal microflora. V. Fecal microbial ecology in ulcerative colitis and regional enteritis: relationship to severity of disease and chemotherapy.

Authors:  S L Gorbach; L Nahas; A G Plaut; L Weinstein; J F Patterson; R Levitan
Journal:  Gastroenterology       Date:  1968-04       Impact factor: 22.682

5.  Hospital food as a possible source of Escherichia coli in patients.

Authors:  E M Cooke; P J Kumar; R A Shooter; S A Rousseau; A L Foulkes
Journal:  Lancet       Date:  1970-02-28       Impact factor: 79.321

6.  Properties of strains of Escherichia coli isolated from the faeces of patients with ulcerative colitis, patients with acute diarrhoea and normal persons.

Authors:  E M Cooke
Journal:  J Pathol Bacteriol       Date:  1968-01

7.  Changing faecal population of Escherichia coli in hospital medical patients.

Authors:  E M Cooke; S Ewins; R A Shooter
Journal:  Br Med J       Date:  1969-12-06
  7 in total
  14 in total

1.  Virulence properties of Escherichia coli strains isolated from patients with inflammatory bowel disease.

Authors:  M H Giaffer; C D Holdsworth; B I Duerden
Journal:  Gut       Date:  1992-05       Impact factor: 23.059

Review 2.  Escherichia coli and ulcerative colitis.

Authors:  D Burke
Journal:  J R Soc Med       Date:  1997-11       Impact factor: 5.344

3.  Serum antibodies to Escherichia coli in subjects with ulcerative colitis.

Authors:  R J Heddle; D J Shearman
Journal:  Clin Exp Immunol       Date:  1979-10       Impact factor: 4.330

4.  Adhesive Escherichia coli in inflammatory bowel disease and infective diarrhoea.

Authors:  D A Burke; A T Axon
Journal:  BMJ       Date:  1988-07-09

5.  Ulcerative colitis and Escherichia coli with adhesive properties.

Authors:  D A Burke; A T Axon
Journal:  J Clin Pathol       Date:  1987-07       Impact factor: 3.411

6.  Effects of sulphasalazine (Salazopyrin) on faecal flora in patients with inflammatory bowel disease.

Authors:  B West; R Lendrum; M J Hill; G Walker
Journal:  Gut       Date:  1974-12       Impact factor: 23.059

7.  Adhesive and hydrophobic properties of Escherichia coli from the rectal mucosa of patients with ulcerative colitis.

Authors:  M G Hartley; M J Hudson; E T Swarbrick; A E Gent; M D Hellier; R H Grace
Journal:  Gut       Date:  1993-01       Impact factor: 23.059

8.  Expression of binding of plasminogen, thrombospondin, vitronectin, and fibrinogen, and adhesive properties by Escherichia coli strains isolated from patients with colonic diseases.

Authors:  W Shen; H Steinrück; A Ljungh
Journal:  Gut       Date:  1995-03       Impact factor: 23.059

9.  Mucosa-associated but not luminal Escherichia coli is augmented in Crohn's disease and ulcerative colitis.

Authors:  Helton Luis de Souza; Vanessa R de Carvalho; Fernando Gomes Romeiro; Ligia Yukie Sassaki; Rogeria Keller; Josias Rodrigues
Journal:  Gut Pathog       Date:  2012-12-13       Impact factor: 4.181

10.  A phylogenetic group of Escherichia coli associated with active left-sided inflammatory bowel disease.

Authors:  Andreas M Petersen; Eva M Nielsen; Eva Litrup; Jørn Brynskov; Hengameh Mirsepasi; Karen A Krogfelt
Journal:  BMC Microbiol       Date:  2009-08-20       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.